FREM2 and glioma: Namely, when compared to expression levels in samples from patients whose disease did not progress, in patients who progressed during first-line temozolomide treatment their FREM2 gene expression levels were halved (p = 0.052) in IDH-mutant gliomas, while there was no change in gene expression levels in IDH-WT glioma samples.